Ibogaine for mental health
A balanced synthesis of the clinical and observational record for ibogaine and noribogaine in mental-health indications, current through October 2, 2026. The central finding is not certainty: the literature is early, heterogeneous, and safety-constrained.
Evidence first. Limits stated plainly.
How to read this page
Ibogaine is a psychoactive alkaloid associated with Tabernanthe iboga; noribogaine is a principal metabolite studied for distinct pharmacologic activity. Published human evidence spans opioid-use outcomes, self-reported trauma symptoms, mood measures, suicidality, and post-concussive complaints. These categories should not be merged into a single claim of mental-health efficacy.
This page separates peer-reviewed clinical and observational reports from regulatory material and from preliminary sources. It also keeps attention on design: sample selection, outcome measures, timing, missing data, concurrent psychotherapy or detoxification, and follow-up can each change what a result means. For broader context on the site’s approach to claims and uncertainty, the main evidence resource sets out the same evidence-first framing.
The U.S. Food and Drug Administration lists ibogaine among Schedule I controlled substances; its Drug Enforcement Administration fact sheet is a regulatory source, not evidence that a treatment works. Regulatory status, research permissions, and availability differ by jurisdiction.
Evidence map
Most reports are not randomized comparisons. That matters because expectancy, selection into treatment, withdrawal management, surrounding care, and incomplete follow-up can all produce apparent change without isolating a drug-specific effect.
Randomization and a credible comparator are the strongest practical tools for separating a treatment effect from time, context, and expectation. A small number of controlled efforts do not yet create a robust mental-health trial base.
Within-person changes can describe feasibility and generate hypotheses, but cannot reliably account for regression to the mean, expectancy, or the effect of co-occurring care.
Case reports may document timing, adverse events, and individual trajectories. They do not estimate population benefit, comparative effectiveness, or a dependable rate of harm.
Naturalistic data can follow real-world pathways, yet treatment selection, attrition, changing exposure, and unmeasured services make causal conclusions uncertain.
By indication
Different endpoints answer different questions. Abstinence, withdrawal scores, PTSD checklists, depression scales, suicidal-ideation items, and post-concussive symptom ratings are not interchangeable measures of mental-health benefit.
The largest body of ibogaine-related clinical observation concerns opioid withdrawal and subsequent substance-use outcomes. Reports include case series, treatment-program cohorts, and follow-up surveys, often with small to moderate samples and without randomized controls. Endpoints commonly include acute withdrawal, self-reported abstinence, or later opioid use rather than a standardized mental-health endpoint.
Some reports describe sizable short-term changes, but estimates are difficult to compare across dosing practices, follow-up windows, retention, and concurrent psychosocial or medical care. Withdrawal-focused material should also be distinguished from psychiatric-outcome evidence; the ibogaine withdrawal evidence discussion addresses that narrower question.
PTSD evidence includes observational reports in selected populations and studies using symptom questionnaires before and after treatment. Reported reductions in checklist scores are signals, not confirmation of efficacy: samples can be self-selected, treatment environments are intensive, and psychotherapy, group support, expectancy, or post-treatment changes may contribute.
There is not yet a large, replicated randomized evidence base establishing ibogaine or noribogaine as PTSD care. For a narrower look at this indication, the PTSD treatment evidence page separates the claims from the unanswered questions.
Depression and anxiety are frequently measured as secondary or exploratory outcomes in naturalistic settings. Improvements on self-report scales may be clinically interesting, but they are not equivalent to diagnostic remission, and results can be affected by baseline severity, concurrent medication changes, expectation, and loss to follow-up.
Noribogaine research has also attracted interest because its pharmacology differs from the parent compound, but mechanistic plausibility does not establish clinical benefit. The National Institute of Mental Health overview of depression underscores that depression is heterogeneous and requires careful measurement in trials.
Evidence addressing suicidal ideation is particularly difficult to interpret because ideation can change quickly and because safety assessment, crisis care, substance use, and social context are major confounders. Small before-and-after reports do not establish prevention of suicide attempts or deaths. Suicidality should therefore remain a distinct outcome, not a proxy for general mood improvement.
For traumatic brain injury and post-concussive symptoms, published observations have included self-reported changes in mood, cognition, sleep, or symptom burden after treatment. There is no established controlled evidence showing that ibogaine treats TBI or post-concussive syndrome. The review of claimed ibogaine benefits is useful only when read with this distinction between reported experience and demonstrated effect.
Limits that change interpretation
Across the literature, the recurring limitations are recognizable: nonrandom allocation, small samples, outcome measures chosen after treatment, selective publication, missing follow-up, unclear adverse-event ascertainment, and variable protocols. Some studies also combine ibogaine with medical detoxification, counseling, residential support, or other substances, making the independent contribution of ibogaine difficult to identify.
Safety reporting needs equal weight. Ibogaine has been associated with cardiac electrophysiology concerns, including QT prolongation; the FDA discussion of QT-related rhythm risk illustrates why cardiac-risk context matters when interpreting any agent with effects on repolarization. It does not make a setting safe or unsafe by itself; screening and monitoring quality must be reported, not presumed.
Priority questions: Can adequately powered randomized trials define benefit against a credible comparator? Which outcomes persist beyond early follow-up? How are concomitant therapies measured? What screening and adverse-event methods are transparent enough to assess risk? And how do findings differ across opioid use, PTSD, mood symptoms, suicidality, and neurologic complaints?
Questions to keep open
Independent interpretation also benefits from context about delivery settings, cultural claims, and jurisdictional differences. The discussion of ibogaine and Bwiti provides relevant cultural context, while a European treatment-setting overview can help distinguish location-specific practice claims from research evidence.
The evidence base is dominated by observational work, case series, open-label studies, and follow-up reports. Randomized controlled evidence remains limited, so effect estimates cannot be treated as settled clinical findings.
Short-term symptom or substance-use changes do not establish durability. Longer follow-up is needed to distinguish transient effects from sustained outcomes and to account for psychotherapy, social support, subsequent treatment, and changes in medication or substance use.
Ibogaine has known cardiac-risk concerns, including QT-interval prolongation, and screening practices vary substantially across settings. Study findings must therefore be read alongside the quality of medical assessment, monitoring, adverse-event reporting, and regulatory status.
Pre-registered protocols, transparent eligibility criteria, independent adverse-event reporting, validated outcome measures, credible comparison groups, documentation of concurrent care, and longer follow-up would all materially improve interpretability. The site’s research priorities outline expands on these study-design needs.
Existing studies provide hypotheses and some reported signals. They do not yet resolve effectiveness, durability, patient selection, comparative value, or safety across mental-health indications. The safety and screening context belongs alongside every interpretation of the evidence.